Remove Biobanking Remove Genome Project Remove Medicine Remove Research
article thumbnail

UK agency pilots biobank to study links between genetics and drug side effects

Pharmaceutical Technology

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1.

article thumbnail

Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data

The Pharma Data

to build a scalable data, analytics, and infrastructure platform This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine. Boehringer Ingelheim partners with Lifebit Biotech, Ltd.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

Both long- and short-read sequencing today is faster, more affordable, and highly accurate, providing researchers with deep insights to fuel research. 2023 is set to usher in a new era of genomics, and here are five areas where we should see significant advances. So, when it comes to proteomics, accuracy is vital.

Genome 115
article thumbnail

Why genomic healthcare data matters in the development of new therapies 

Drug Discovery World

Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies – precision medicines. In April 2003, after its launch in October 1990, the project was completed, generating the first sequence of the human genome.

Genome 98
article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

One of the reasons is because researchers now have far more genetic data to work with than was ever previously possible. The cost of testing per human genome in 2006 was approximately $14 million , and in less than two decades, an average consumer-purchased genetic test costs $100.

article thumbnail

Estonia National Biobank to sequence 10,000 whole genomes 

Drug Discovery World

Founded in 2000, the Estonian Biobank holds more than 212,000 samples – 20% of the country’s adult population – reflecting its age, sex, and geographical distribution. To date, the samples for the Biobank have been genotyped using microarray-based methods.